{"id":3571,"date":"2021-08-12T18:43:26","date_gmt":"2021-08-12T18:43:26","guid":{"rendered":"https:\/\/www.spanglobalservices.com\/data\/?page_id=3571"},"modified":"2024-03-07T07:48:55","modified_gmt":"2024-03-07T07:48:55","slug":"pharma-investors","status":"publish","type":"page","link":"https:\/\/www.spanglobalservices.com\/data\/pharma-investors\/","title":{"rendered":"Pharma-Investors"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n
\n
\n
\n

Give your Big Business Idea & Go-To-Market Strategy the Right Push : Reach Pharma & Healthcare Investors and Venture Capitalists Globally<\/h1>\n

Ride the Tide Towards 10 Fold Growth<\/h4>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n
\n
\n
\n
\n
\n
\n

\"\"<\/h1>\n

<\/h4>\n

<\/h4>\n

<\/h4>\n

<\/h4>\n

<\/h4>\n

<\/h4>\n

<\/h4>\n

<\/h4>\n

<\/h4>\n

<\/h4>\n

Target the Most Prospective Decision Makers by Tapping into Pharma & Healthcare Investor Intelligence<\/h4>\n

We can help you with a comprehensive and custom database of Pharma & Healthcare Investors that helps you make the right connections between Pharma & Healthcare Investors, projects and opportunities.<\/p>\n

Our intelligence on Pharma & Healthcare Investor investments, investment types, investment stage, portfolios, exits, fund performance, teams and co-Pharma & Healthcare Investors help you align with global investment ecosystems.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n

5<\/span>M<\/h2>\n

Global Pharma Companies Data<\/p>\n<\/div>\n<\/div>\n

\n
\n

12<\/span>K<\/h2>\n

Technology Vendors Serviced<\/p>\n<\/div>\n<\/div>\n

\n
\n

50<\/span>K<\/h2>\n

Technology Modules Implemented<\/p>\n<\/div>\n<\/div>\n

\n
\n

6.2<\/span>K<\/h2>\n

Projects Served<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n

We Have Compiled a Comprehensive Snapshot Pharma & Healthcare Investors for You<\/strong><\/h4>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Investment Type Breakdown<\/th>\nCompanies<\/th>\n<\/tr>\n
Venture Capital<\/td>\n13411<\/td>\n<\/tr>\n
Individual\/Angel<\/td>\n23115<\/td>\n<\/tr>\n
Private Equity Firm<\/td>\n6816<\/td>\n<\/tr>\n
Accelerator<\/td>\n2109<\/td>\n<\/tr>\n
Investment Partner<\/td>\n15631<\/td>\n<\/tr>\n
Corporate Venture Capital<\/td>\n711<\/td>\n<\/tr>\n
Micro VC<\/td>\n2047<\/td>\n<\/tr>\n
Angel Group<\/td>\n1280<\/td>\n<\/tr>\n
Incubator<\/td>\n1149<\/td>\n<\/tr>\n
Investment Bank<\/td>\n1142<\/td>\n<\/tr>\n
Family Investment Office<\/td>\n683<\/td>\n<\/tr>\n
Venture Debt<\/td>\n298<\/td>\n<\/tr>\n
Co-Working Space<\/td>\n185<\/td>\n<\/tr>\n
Fund Of Funds<\/td>\n260<\/td>\n<\/tr>\n
Hedge Fund<\/td>\n402<\/td>\n<\/tr>\n
Government Office<\/td>\n396<\/td>\n<\/tr>\n
University Program<\/td>\n225<\/td>\n<\/tr>\n
Entrepreneurship Program<\/td>\n215<\/td>\n<\/tr>\n
Secondary Purchaser<\/td>\n47<\/td>\n<\/tr>\n
Startup Competition<\/td>\n60<\/td>\n<\/tr>\n
Syndicate<\/td>\n107<\/td>\n<\/tr>\n
Pension Funds<\/td>\n38<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Investment Stage Breakdown<\/th>\nCompanies<\/th>\n<\/tr>\n
Seed<\/td>\n21438<\/td>\n<\/tr>\n
Early Stage Venture<\/td>\n11320<\/td>\n<\/tr>\n
Late Stage Venture<\/td>\n3503<\/td>\n<\/tr>\n
Venture<\/td>\n2107<\/td>\n<\/tr>\n
Private Equity<\/td>\n3857<\/td>\n<\/tr>\n
Crowd Funding<\/td>\n378<\/td>\n<\/tr>\n
Debt<\/td>\n887<\/td>\n<\/tr>\n
Grant<\/td>\n299<\/td>\n<\/tr>\n
Non-Equity Assistance<\/td>\n299<\/td>\n<\/tr>\n
Convertible Note<\/td>\n695<\/td>\n<\/tr>\n
Secondary Market<\/td>\n382<\/td>\n<\/tr>\n
Post-IPO<\/td>\n262<\/td>\n<\/tr>\n
Initial Coin Offering<\/td>\n205<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n

 <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Investments at this Funding Stage<\/th>\nCompanies<\/th>\n<\/tr>\n
Pre-Seed<\/td>\n5251<\/td>\n<\/tr>\n
Seed<\/td>\n25361<\/td>\n<\/tr>\n
Series A<\/td>\n17447<\/td>\n<\/tr>\n
Series B<\/td>\n10681<\/td>\n<\/tr>\n
Series C<\/td>\n6374<\/td>\n<\/tr>\n
Angel<\/td>\n9264<\/td>\n<\/tr>\n
Private Equity<\/td>\n2887<\/td>\n<\/tr>\n
Debt Financing<\/td>\n1988<\/td>\n<\/tr>\n
Convertible Note<\/td>\n2433<\/td>\n<\/tr>\n
Grant<\/td>\n1621<\/td>\n<\/tr>\n
Corporate Round<\/td>\n2101<\/td>\n<\/tr>\n
Equity Crowd Funding<\/td>\n305<\/td>\n<\/tr>\n
Product Crowd Funding<\/td>\n18<\/td>\n<\/tr>\n
Secondary Market<\/td>\n372<\/td>\n<\/tr>\n
Post-IPO Equity<\/td>\n2514<\/td>\n<\/tr>\n
Post-IPO Debt<\/td>\n400<\/td>\n<\/tr>\n
Post-IPO Secondary<\/td>\n76<\/td>\n<\/tr>\n
Non-equity Assistance<\/td>\n255<\/td>\n<\/tr>\n
Initial Coin Offering<\/td>\n2076<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

1,24,072 Pharma & Healthcare Investor Companies\u2019 Contacts Are Ready For Your Targeting<\/h4>\n

Our offsite teams can also help you extend your reach by setting up multi-channel campaigns using email, telemarketing, social campaigns and more.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

Pharma & Healthcare Investor Focused Top Industry Vertical<\/h4>\n